Pharmacoeconomics of Treatment Patients with High Level Hypercholesterolemia


This review highlights the principles of early diagnosis and treatment of patients with heterozygous familial hypercholesterolemia. Innovative and highly efficient technologies exist for prevention of the atherosclerotic process in the arterial part of the vascular system, its inhibition and elimination. They help to stabilize the patient's condition and to reduce the target organs damage. The treatment strategy, described in this review, is effective in terms of cure and pharmacoeconomics. It decreases the risk of atherosclerotic cardiovascular disease (ASCVD) and its complications in patients. The positive outcomes are the decrease of exposure to extreme level of LDL-C, reduction of the cumulative burden of disease and mortality rate, the extension of patients' life expectancy.

Conflict of Interest:nothing to disclose.

Список литературы

1. Vuorio A, Doherty KF, Humphries SE et al. Statin treatment of children with familial hypercholesterolemia – trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis. 2013;226:315–20.

2. Mc Crindle BW. Familial hypercholesterolemia in children and adolescents. Curr Opin Lipidol.2012;23:525–31.

3. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50:172–177.

4. Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. EurHeartJ. 2013;34(45):3478-90a.

5. Kukharchuk VV, Malyshev PP, Meshkov AN. Familial hypercholesterolemia: modern aspects of diagnosis, prevention and therapy. Kardiologiya.2009;1:76-83. (In Russ.). 

6. Sijbrands EJ, Westendorp RG, Paola Lombardi M et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis. 2000;149(2):421-5.

7. Toth PP Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int. J. Clin. Pract. 2008;62 8):1246-1254.

8. Ezhov MV, Sergienko IV, Rozhkova TA et al.Russian recommendations for the diagnosis and treatment of familial hypercholesterolemia. Ateroskleroz i dislipidemii.2016;4:21–9.(In Russ.). 

9. Catapano AL, Graham I, De Backer G et al. Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J.2016;37(39):2999-3058.

10. Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168:1–14.

11. Familial hypercholesterolaemia: report of a WHO consultation. Paris: World Health Organisation; 1997.

12. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004;160(5):421-9.

13. Plans-Rubio P. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices. AmJCardiovascDrugs. 2010;10:369–382.

14. Gilyarevsky SR, Orlov VA. Use of treatment efficacy analysis for clinical decision making in cardiology. Kardiologiya. 1997;9:70-80.(In Russ.).

15.Economic evaluation of the effectiveness of drug therapy (pharmaco-economic analysis). Ed. Prof. Vorobyev PA, M., 2000. (In Russ.).

16.Marks D, Wonderling D, Thorogood M et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ. 2002;324:1303.

17.Nherera L, Calvert NW, Demott K et al. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin. 2010;26:529–536.

18. Nherera LM. Saving lives, saving families: the health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH). Economics Chapter: Estimating the benefits from treatment and increasing the implementation of cascading screening. URL:

19. Kusters DM, de Beaufort C, Widhalm K et al. Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child. 2012;97:272–276.doi: 10.1136/archdischild-2011-300081

20. Elis A, Zhou R, Stein EA. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J Cardiol. 2011;108:223–6.

21. Ademi Z, Watts GF, Juniper A, Liew D. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol. 2013;167:2391–6.

22. McConnachie A, Walker A, Robertson M et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur Heart J. 2014;35:290–298.

23. Stevanovic J, O'Prinsen AC, Verheggen BG et al. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands. Clin Ther. 2014;36:368–384.e5.

24. Banegas JR, Lopez-Garcia E, Dallongeville J et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J.2011;32:2143–2152.

25. Kotseva K, Wood D, De Backer G et al. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010;17:530–540.

26. Cherry SB, Benner JS, Hussein MA et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health. 2009;12:489–497.

27. Corrao G, Scotti L, Zambon A et al.Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. Atherosclerosis. 2011;217:479–485.

28. Dragomir A, Cote R, Roy L et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48:418–425.

29. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ.2003;326:1419.

30. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006:368:679–686.

31. Van Gils PF, Over EA, Hamberg-van Reenen HH et al. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open. 2011;1:e000363.

32. Nherera L, Marks D, Minhas Ret al. Probabilistic costeffectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 2011;97:1175–118.

33. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.

34. Watts GF, Sullivan DR, Poplawski N et al. Familial hypercholesterolaemia: a model of care for Australasia. Atherosclerosis. 2011;12:221–263.

35. Pijlman AHHuijgen RVerhagen SNet al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010;Mar;209(1):189-94.doi: 10.1016/j.atherosclerosis.2009.09.014

36. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50:172–177.

37. Schmidt AF, Pearce LS, Wilkins JT et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst. 2017;4:CD011748.doi: 10.1002/14651858.CD011748.pub2

38. Gabriel Steg on behalf of ODYSSEY OUTCOMES Investigators. Oral presentation at 67th Scientific Sessions of American College of Cardiology (March 10, 2018). Orlando (Florida), USA. URL: (date of access March 14, 2018).

39. LandmesserU,ChapmanMJ et al. Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur. Heart J. 2018;39(14):1131-1143.doi:10.1093/eurheartj/ehx549

40. Sabatine MS, Leiter LA, Wiviott SD et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. LancetDiabetesEndocrinol. 2017;5:941-950.

41. Diagnosis and correction of lipid metabolism disorders in order to prevent atherosclerosis. Russian recommendations, VI revision. Ateroskleroz i dislipidemii.2017;3:5-22. (In Russ.).

42. Wiviott SD, Cannon CP, Morrow DA et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J. Am. Coll. Cardiol. 2005;46(8):1411-1416.doi: 10.1016/j.jacc.2005.04.064 

43. Ezhov MV, Lazareva NV, Sagaydak OV et al. The frequency of lipid metabolism disorders and the use of statins in acute coronary syndrome (according to the Federal Register of acute coronary syndrome). Ateroskleroz i dislipidemii.2018;1:47-57. (In Russ.).

44. Rallidis LS, Triantafyllis AS, Tsirebolos G et al. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins. Atherosclerosis. 2016;249:17-21.doi: 10.1016/j.atherosclerosis.2016.03.023

45. Serban M.C. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J. Am. Coll. Cardiol. 2017;69(11):1386-1395.doi: 10.1016/j.jacc.2016.12.03

46. Schwartz GGBessac LBerdan LGet al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. AmHeartJ. 2014;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028

47. Zyryanov SK, Dyakov IN. Inferred economic effect of the use of alirocumab in patients with hypercholesterolemia and high cardiovascular risk. Klinicheskaya farmakolologiya i terapiya. 2018;27(1):90-96. (In Russ.).

Для цитирования

Fatenkov OV, Panisheva YaA, Galkina MA, Sytdykov IKh. Pharmacoeconomics of Treatment Patients with High Level HypercholesterolemiaScience & Innovations in Medicine. 2019;Vol.4(1):26-31.


Send an online application form to the publication